Drugs / Acyline
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00471185 | Jun → Aug 2007 | — | University of Washington | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00603187 | Jan → Feb 2008 | — | University of Washington | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00729859 | Dec 2008 → May 2010 | — | University of Washington | Completed | Missed primary |
| Comparator or background therapy14 trials | ||||||
| Phase 1 | NCT01167829 Background | Jul → Oct 2010 | — | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT00663793 Background | Oct 2008 → May 2009 | hypogonadism | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT00161486 Comparator | Jul → Nov 2004 | hypogonadism | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT01686828 Background | Jun 2013 → May 2015 | hypogonadism, obesity disorder, type 2 diabetes mellitus | University of Washington | Completed | Missed primary |
| Phase 1/2 | NCT01215292 Background | Jan 2011 → Mar 2012 | — | University of Washington | Completed | Met primary |
| Phase 1/2 | NCT00839319 Background | Mar 2009 → Sep 2010 | — | University of Washington | Completed | Met primary |
| Phase 1/2 | NCT00156650 Comparator | Dec 2004 → Jul 2005 | — | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT00161447 Comparator | May 2004 → Apr 2006 | — | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT02147964 Background | Jun 2019 → Dec 2021 | hypogonadotropic hypogonadism | University of Washington | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT00842751 Comparator | Jul → Nov 2009 | — | University of Washington | Completed | No outcome recorded |
| Phase 2/3 | NCT01327495 Comparator | Oct 2011 → Jun 2014 | — | University of Washington | Completed | No outcome recorded |
| — | NCT02758431 Comparator | Jul 2016 → Jan 2023 | hypogonadism | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT00983554 Background | Jun 2005 → May 2009 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Unknown | No outcome recorded |
| — | NCT00470990 Background | Oct 2002 → Jun 2008 | hypogonadism | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acyline | “Acyline 300 µg/kg subcutaneous injections every 2 weeks” NCT00983554 ↗ |
| Known as | MER-104 | “GIPET enhanced oral acyline (MER-104)” NCT00471185 ↗ |
| Action | Inhibit | “the gonadotropin releasing hormone (GnRH) antagonist acyline” PMID 17494097 ↗ May 20071“Gonadotropin-releasing hormone receptor antagonist” CHEMBL262747 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL262747 ↗ |
| Route | Subcutaneous | “acyline (300 microg/kg subcutaneously every 2 weeks for 12 weeks)” PMID 17494097 ↗ May 2007 |
| Target | GNRHR | “Gonadotropin-releasing hormone receptor antagonist” CHEMBL262747 ↗ |